Wall Street brokerages expect BioScrip, Inc. (NASDAQ:BIOS) to post sales of $219.72 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for BioScrip’s earnings, with estimates ranging from $209.92 million to $226.65 million. BioScrip posted sales of $232.46 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 5.5%. The company is scheduled to report its next earnings report before the market opens on Tuesday, August 8th.

According to Zacks, analysts expect that BioScrip will report full-year sales of $219.72 million for the current financial year, with estimates ranging from $820.66 million to $877.20 million. For the next fiscal year, analysts anticipate that the firm will report sales of $808.11 million per share, with estimates ranging from $765.25 million to $865.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow BioScrip.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Thursday, May 4th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.04. The firm had revenue of $217.80 million for the quarter, compared to analyst estimates of $230.23 million. The business’s revenue for the quarter was down 8.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.17) earnings per share.

Several brokerages have issued reports on BIOS. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Zacks Investment Research lowered shares of BioScrip from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Finally, Barrington Research boosted their price target on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a report on Monday, June 26th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $3.50.

Several large investors have recently bought and sold shares of BIOS. Roanoke Asset Management Corp NY raised its stake in BioScrip by 72.9% in the second quarter. Roanoke Asset Management Corp NY now owns 403,280 shares of the company’s stock valued at $1,095,000 after buying an additional 170,000 shares during the last quarter. Sheets Smith Wealth Management raised its stake in BioScrip by 13.4% in the second quarter. Sheets Smith Wealth Management now owns 125,328 shares of the company’s stock valued at $340,000 after buying an additional 14,820 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock valued at $109,000 after buying an additional 25,500 shares during the last quarter. Wynnefield Capital Inc. raised its stake in BioScrip by 2.7% in the first quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock valued at $6,460,000 after buying an additional 100,000 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in BioScrip by 5.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 488,076 shares of the company’s stock valued at $830,000 after buying an additional 23,598 shares during the last quarter. 83.06% of the stock is currently owned by institutional investors and hedge funds.

Shares of BioScrip (BIOS) opened at 2.94 on Thursday. BioScrip has a 12 month low of $0.98 and a 12 month high of $3.43. The company’s market capitalization is $355.69 million. The company has a 50-day moving average of $2.71 and a 200 day moving average of $1.92.

TRADEMARK VIOLATION WARNING: “BioScrip, Inc. (BIOS) Expected to Announce Quarterly Sales of $219.72 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/27/bioscrip-inc-bios-expected-to-announce-quarterly-sales-of-219-72-million-2.html.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.